Baird Maintains Neutral on CRISPR Therapeutics, Raises Price Target to $52
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Jack Allen maintains a Neutral rating on CRISPR Therapeutics (CRSP) and raises the price target from $46 to $52.

May 09, 2024 | 10:41 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baird analyst Jack Allen maintains a Neutral rating on CRISPR Therapeutics and raises the price target from $46 to $52.
The increase in price target by Baird, while maintaining a Neutral rating, suggests a positive adjustment in the valuation of CRISPR Therapeutics. This adjustment reflects an expectation of improved performance or valuation metrics, which could lead to increased investor interest and potentially a short-term uptick in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 90